Taurus Large Cap Fund
Direct · GrowthAI Summary
Taurus Large Cap Fund has delivered a 3Y SIP XIRR of 13.44% and a 5Y SIP XIRR of 12.35%, but these trail the category average SIP XIRR of 14.28% and 14.04% respectively across all time horizons. Against the NIFTY 50, the fund shows positive alpha over 1Y (8.25%), 3Y (6.39%) and 5Y (3.19%), though alpha fades to near zero over 10Y (-0.41%) and 15Y (-0.01%), indicating benchmark-level returns only over the long run. The lump-sum Fund CAGR of 14.11% over 3Y versus the benchmark's 7.75% reflects strong recent relative performance.
The fund exhibits a beta below 1 (0.89-0.99 across windows) with downside capture consistently under 100% (86.39% over 1Y, 94.95% over 3Y), suggesting it falls less than the index in corrections. It has experienced 10 drawdown events greater than 10%, and the recovery from maximum drawdown took 233 days, indicating meaningful downside episodes despite controlled capture ratios. Calmar ratios between 0.29 and 0.37 across horizons point to moderate risk-adjusted efficiency.
The portfolio holds 39 stocks with the top 10 accounting for roughly 53% of NAV, led by Divi's Laboratories (8.58%), ITC (7.60%) and ICICI Bank (6.79%). Banks dominate sector allocation at 22.0%, followed by Pharmaceuticals (9.7%), FMCG (9.1%) and IT (8.9%), giving a financials-heavy but otherwise reasonably diversified spread. Holdings like Sigma Advanced Systems (Aerospace & Defense, 4.78%) and Advit Jewels (4.59%) add some non-traditional large cap exposure.
The fund underperforms the category average SIP XIRR at every measured horizon — for example 11.67% vs 14.37% over 10Y and 11.60% vs 14.11% over 12Y — placing it in the lower half of its peer group on SIP returns. Calendar year returns show inconsistency, ranging from 38.60% in 2014 to -4.99% in 2018 and -3.58% in 2013. Its high expense ratio of 2.32% is a likely drag relative to peers and may explain part of the category shortfall.
This fund may suit conservative large cap investors who prioritize downside protection, given its sub-1 beta and downside capture below 100%, and who can stay invested for 7-10 years. However, investors seeking category-beating SIP returns should note the consistent gap versus peers and the elevated 2.32% expense ratio. A moderate risk tolerance is appropriate, as the fund has seen 10 drawdowns exceeding 10% historically.
- Consistently low downside capture (86.39% over 1Y, 94.95% over 3Y) with beta below 1, indicating better-than-index resilience in falling markets
- Strong recent alpha versus NIFTY 50 of 8.25% over 1Y and 6.39% over 3Y, with 3Y Fund CAGR of 14.11% versus the benchmark's 7.75%
- Diversified 39-stock portfolio with a balanced spread across banks, pharma, FMCG and IT beyond the dominant financials allocation
- SIP XIRR trails the category average at every horizon (e.g., 11.67% vs 14.37% over 10Y), signaling persistent underperformance versus peers
- High expense ratio of 2.32% erodes returns, and alpha diminishes to near zero over 10Y (-0.41%) and 15Y (-0.01%) horizons
Generated on 03-09-2026, 3:11 AM. Verify before investing.
Gives more importance to longer time periods (10Y, 20Y) than shorter ones (1Y, 3Y). This balances out recent outperformance and gives a more realistic picture of what long-term returns might look like.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
If you invested ₹1,00,000 every month via SIP, here's how this fund has historically performed across different time horizons.
| Duration | Invested | Median Value | XIRR | Min XIRR | Max XIRR |
|---|---|---|---|---|---|
| 1 Year | ₹12.00 L | ₹12.60 L | 13.9% | -55.7% | 71.7% |
| 3 Years | ₹36.00 L | ₹42.20 L | 11.1% | -22.0% | 28.4% |
| 5 Years | ₹60.00 L | ₹78.87 L | 10.8% | -10.6% | 23.2% |
| 7 Years | ₹84.00 L | ₹1.23 Cr | 10.9% | -4.0% | 18.5% |
| 10 Years | ₹1.20 Cr | ₹2.21 Cr | 11.6% | 7.6% | 14.9% |
| 12 Years | ₹1.44 Cr | ₹2.98 Cr | 11.5% | 9.4% | 13.4% |
SIP returns vs benchmark & category
Annualised SIP return (XIRR) over each rolling horizon — like-for-like, not lump-sum.
| Duration | Fund SIP XIRR | NIFTY 50 | Category avg | Fund edge |
|---|---|---|---|---|
| 1 Year | 13.9% | 14.4% | 14.1% | -0.6% |
| 3 Years | 11.1% | 11.1% | 14.3% | -0.0% |
| 5 Years | 10.8% | 10.4% | 14.0% | +0.4% |
| 7 Years | 10.9% | 10.6% | 14.1% | +0.3% |
| 10 Years | 11.6% | 11.5% | 14.4% | +0.1% |
| 12 Years | 11.5% | 11.4% | 14.1% | +0.1% |
| Duration | Mean | Median | Min | Max | Sharpe | Sortino | % Positive | Cat. Mean | Cat. Median |
|---|---|---|---|---|---|---|---|---|---|
| 1 Year | 13.0% | 8.2% | -30.6% | 73.7% | 0.38 | 0.99 | 80% | — | — |
| 3 Years | 11.3% | 12.1% | -8.2% | 24.5% | 0.87 | 2.14 | 95% | — | — |
| 5 Years | 10.7% | 10.8% | -3.4% | 23.5% | 0.94 | 2.95 | 99% | — | — |
| 10 Years | 11.0% | 10.8% | 8.0% | 13.7% | 3.82 | — | 100% | — | — |
Calmar Ratio by Duration
Compared against NIFTY 50
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +8.25 | 0.89 | 97.9% | 86.4% | 6.4% | -2.9% |
| 3 Years | +6.39 | 0.98 | 102.8% | 95.0% | 14.1% | 7.8% |
| 5 Years | +3.19 | 0.99 | 100.6% | 96.7% | 11.0% | 7.8% |
| 7 Years | +1.58 | 0.93 | 95.2% | 93.4% | 13.0% | 11.8% |
| 10 Years | -0.41 | 0.94 | 94.9% | 95.0% | 10.1% | 10.8% |
| 12 Years | +0.59 | 0.95 | 95.5% | 94.4% | 10.2% | 9.8% |
| 15 Years | -0.01 | 0.95 | 95.9% | 95.6% | 9.6% | 9.7% |
| # | Stock | % of NAV |
|---|---|---|
| 1 | Divi's Laboratories Ltd. | 8.58% |
| 2 | ITC Ltd. | 7.60% |
| 3 | ICICI Bank Ltd. | 6.79% |
| 4 | HDFC Bank Ltd. | 5.54% |
| 5 | Sigma Advanced Systems Ltd. | 4.78% |
| 6 | Advit Jewels Ltd. | 4.59% |
| 7 | Bharti Airtel Ltd. | 4.46% |
| 8 | Reliance Industries Ltd. | 3.97% |
| 9 | State Bank of India | 3.59% |
| 10 | HCL Technologies Ltd. | 3.48% |